Will Hydroxychloroquine Impede or Prevent COVID-19

You may be eligible if

• 1. Participant is willing and able to provide informed consent.
• 2. Participant is 18-75 years of age.
• 3. Participant does not have symptoms of respiratory infection, including cough, fevers (temperature \>38.0C), difficulty breathing, shortness of breath, chest pains, malaise, myalgia, headaches, nausea or vomiting, or other symptoms associated with COVID-19.
• 4. Participant is willing to provide blood samples for the study.
• 5. Subject agrees to all aspects of the study.
• 2. Participant unable or unwilling to provide informed consent.
• 3. Participant has any of the symptoms above or screens positive for possible COVID-19 disease.
• 4. Participant is currently enrolled in a study to evaluate an investigational drug.
• 5. Vulnerable populations deemed inappropriate for study by the site Principal Investigator.
• 6. The participant has a known allergy/hypersensitivity or has a medication or co-morbidity (including history of gastric bypass, epilepsy, cardiovascular disease or renal failure) that prevents the use of HCQ (see pharmacy section).
• 7. The participant is a woman of childbearing age whose pregnancy status is unknown and is not willing to use 2 methods of contraception.
• 8. The participant is pregnant or nursing.
• 9. The participant was diagnosed with retinopathy prior to study entry.
• 10. The participant has a diagnosis of porphyria prior to study entry.
• 11. The participant has renal failure with a creatinine clearance of \<10 ml/min, pre-dialysis or requiring dialysis.
• 12. The Participant has a family history of Sudden Cardiac Death.
• 13. The participant is currently on diuretic therapy.
• 14. The participant has a history of known Prolonged QT Syndrome.
• 15. The participant is already taking any of the following medications: Abiraterone acetate, Agalsidase, Amodiaquine, Azithromycin, Conivaptan, Dabrafenib, Dacomitinib, Dapsone (Systemic), Digoxin, Enzalutamide, Fusidic Acid (Systemic), Idelalisib, Lanthanum, Lumefantrine, Mefloquine, Mifepristone, Mitotane, Pimozide, QT-prolonging Agents, Stiripentol).